Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
AGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)1.08M
Market Cap
$144.98M
Enterprise Value$540.01M
Total Cash (Recent Filing)$9.53M
Total Debt (Recent Filing)$402.76M
Price to Earnings (P/E)―
Beta3.16
Next Earnings
Nov 11, 2025EPS Estimate
0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding31,864,107
10 Day Avg. Volume652,319
30 Day Avg. Volume1,083,763
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.72
Enterprise Value/Revenue5.31
Enterprise Value/Gross Profit-1.12K
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$10.25Price Target Upside125.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial Design And FDA AlignmentThe FDA aligned on a two-arm Phase III design evaluating bot/bal versus best supportive care, which is in line with the overall Phase III trial design proposed by Agenus.
Partnership And Capital InfusionThe partnership agreement with Zydus Lifesciences provides a significant cash infusion for Agenus, relieving near-term capital constraints.
Strategic CollaborationThe collaboration combines Agenus' R&D capabilities with Zydus' manufacturing and commercial strength, particularly in the growing Indian market.
Bears Say
Clinical Trial RisksGiven that about 70% of MSS mCRC patients have liver metastases, where outcomes tend to be worse, there is potential risk to achieving statistical significance in all-comers.
Efficacy ConcernsThe FDA reiterated that the demonstrated magnitude of treatment effect does not appear to meet the standard of reasonably likely to predict benefit.
Regulatory Approval UncertaintyAnalyst remains Neutral until updates are provided on path to market and a better sense of if the FDA's advice has changed since last year.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $1.38 and its highest was $7.34 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $144.98M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 11, 2025 which is in 87 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 11, 2025. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of $2.42 by -$3.42.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is 0.51.
How many shares outstanding does Agenus have?
Agenus has 31,864,107 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$1 in its last earnings report, missing expectations of $2.42. Following the earnings report the stock price went down -11.042%.
Which hedge fund is a major shareholder of Agenus?
Among the largest hedge funds holding Agenus’s share is Oracle Investment Management Inc. It holds Agenus’s shares valued at 0.
Agenus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.25 (125.27% Upside)
$10.25 (125.27% Upside)
Blogger Sentiment
Neutral
AGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.65%
12-Months-Change
Fundamentals
Return on Equity
260.68%
Trailing 12-Months
Asset Growth
-36.66%
Trailing 12-Months
Company Description
Agenus
Agenus (AGEN) is a biotechnology company focused on the discovery and development of immuno-oncology therapies to treat cancer. The company operates in the biopharmaceutical sector, primarily developing innovative treatments that harness the body’s immune system to fight tumors. Agenus has a diverse portfolio of product candidates, including monoclonal antibodies, cell therapies, and personalized vaccines aimed at enhancing immune response against various cancer types.
AGEN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented significant advancements in leadership, operational efficiency, and promising clinical data for BOT/BAL, despite ongoing financial losses and cash balance concerns. The strategic transactions and new data provide optimism for future growth and regulatory success. However, past regulatory challenges and financial constraints remain points of concern.View all AGEN earnings summariesAGEN Stock 12 Month Forecast
Average Price Target
$10.25
▲(125.27% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Fortress Biotech
―
Outlook Therapeutics
―
Quince Therapeutics
―
Ownership Overview
2.97% Insiders
15.37% Mutual Funds
0.14% Other Institutional Investors
76.69% Public Companies and
Individual Investors